Who Is Getting Fit This Year?

[Hom3r]

Originally Posted by thenry

Bad news. I had to attend an appointment early this morning for my lower back. They wanted to sign me off work with disc relapse and sciatic symptoms. I've been referred to a physio again, I last saw one in 2024 who taught me pilates but that's proving useless. Pain killers don't work. Relief patches do nothing. My eyes go blurry during pain.

Getting fit my arse

Have you looked into acupuncture.

[thenry]

Originally Posted by Hom3r

Have you looked into acupuncture.

Nope. I don't have a clue. I've been referred to a physiotherapist who will discuss my options with me.

[thenry]

I got my front and rear suspension serviced by TF tuned. No excuses not to get fit and get rid of all these health issues.

[thenry]

Where's Russ gone?

He rarely visits much, last seen at the end of April.

[thenry]

Shame. I wanted to ask him about Retatrutide. He went on weight loss jabs.

[papa smurf]

Originally Posted by thenry

Shame. I wanted to ask him about Retatrutide. He went on weight loss jabs.

what does your doctor say about it ?

[thenry]

Originally Posted by papa smurf

what does your doctor say about it ?

I don't know. I haven't asked.

I did query weight loss jabs but they told me I don't fall into the category to justify jabs. I'm obese. I do.

[TheDaddy]

Originally Posted by thenry

Shame. I wanted to ask him about Retatrutide. He went on weight loss jabs.

You sure it was Russ? Doubt he has ever needed fat shots tbh

[thenry]

Yup search Russ in this thread...

Originally Posted by Russ

So I’ve upped my Ozempic dosage from 10 clicks to 51 (I was previously using a very dose) and for the first 24 hours I couldn’t keep off the toilet, it was non-stop. I swear I’d have lost a stone just from that.

Since then I just get through protein cornflakes for breakfast, 4 water protein shakes and a single chicken filet in the evening and my gut has virtually disappeared, in total I’ve dropped just over a stone and a half since the start of May whilst retaining the muscle which I’m dn happy about. V shape is there and my cardio is doing really well. Happy (and more cut) Russ.

[tweetiepooh]

Just wanting to get back to the gym after preferring to go for walks in the lovely evenings and I develop another Achilles tendonopathy.

[thenry]

My journey on retatrutide begins today. I've stacked it with cagrilintide.

My weight today is 96kg.

2.5mg reta
0.5 cag

Wish me luck

Originally Posted by thenry

My journey on retatrutide begins today. I've stacked it with cagrilintide.

My weight today is 96kg.

2.5mg reta
0.5 cag

Wish me luck

Are you on a clinical trial with retatrutide and/or cagrilintide, as neither of them are licensed in the UK, and only licenced for Stage 3 trials in the USA?

Also, stacking them is only at the pre-clinical stage in current research (animal testing) - it’s not been tested on humans…

[thenry]

I'm administering it for educational purposes. That old chestnut I know.

The drug has been given soo many thumbs up it's hard to ignore being honest. I wasn't particularly interested in manjaro. Russ was on similar who justified the negatives with clear to see results but that wasn't enough to get me on it.

This retatrutide has three points of interest. It does a lot more than the traditional manjaro.

Have any of these "thumbs up" been from actual medical research scientists?

Just to clarify - you’re buying unlicensed untested weight-loss drugs from illegal sources, have no idea if the drugs you’re buying are actually retatrutide or cagrilintide (unlikely that they are, as I can’t see Eli Lilly or Novo Nordisk providing them) or what’s actually in them, and you are then going to stack them in a way that’s never been clinically tested, even on animals?

The cagrilintide-semaglutide stack has been clinically tested, but that’s not what you’re going to try.

I believe this approach to weight-loss may be sub-optimal, for the reasons below…

https://formblends.com/articles/reta...ilintide-combo

Can You Stack Retatrutide With Cagrilintide? The Honest Answer

The short answer up front

No clinical trial has combined retatrutide and cagrilintide. No FDA-approved combination exists. Combining them outside supervised research is not safe and is not endorsed by any clinical guideline. Patients asking the stacking question should work with a licensed clinician on FDA-approved options instead.

Key Takeaways

Cagrilintide is an amylin analog. Retatrutide is a triple incretin agonist. Their mechanisms are non-overlapping, which is what fuels the stacking question
Cagrilintide is owned by Novo Nordisk and is being developed in the cagrisema combination with semaglutide. It is not approved as a standalone

Retatrutide is owned by Eli Lilly and is in phase 3 trials. It is not approved
No published trial combines the two molecules. The cross-company ownership makes such a trial commercially unlikely

Stacking investigational peptides outside trial enrollment exposes the patient to unverified product, unknown pharmacology, and zero clinical oversight

Direct answer

Patients asking whether they can take cagrilintide and retatrutide together are usually working from a peptide-stacking framework popular on certain online communities. The framework is not how clinical pharmacology works. Two drugs that look promising on their own do not automatically add up to a better drug when combined. Combinations require their own trials to characterize safety, efficacy, dosing, and interactions. For retatrutide and cagrilintide, no such trial exists. The responsible answer is to wait for clinical evidence rather than self-experiment with unapproved peptides.

What "stacking" actually means in patient inquiries

The peptide-stacking framework that drives this question typically involves:

Sourcing peptides from gray-market suppliers marketing "research chemicals" not for human use

Self-injecting at doses derived from social media or community forum posts

Combining two or more peptides on assumed-additive logic

Skipping clinical monitoring

This pattern carries multiple categories of risk:

Product identity. Gray-market peptides are not tested for purity or identity. Lab analyses of community-supplied peptides have shown wide variability, with some products containing little to none of the labeled compound and others containing bacterial endotoxin or contaminants

Dosing. Without titration protocols, patients commonly start at doses that produce severe adverse events, then either abandon treatment or continue through symptoms they should have stopped for

Drug interactions. Other medications (insulin, sulfonylureas, anticoagulants, etc.) interact with incretin and amylin agonists in ways that require clinical oversight to manage safely

Adverse event support. If a serious adverse event occurs, the patient has no documentation of what they took, at what dose, when. ER physicians cannot effectively treat what they cannot identify

Concrete risks of combining unapproved peptides

Specific clinical concerns when stacking incretin and amylin agonists outside supervision:

Severe gastroparesis. Both drug classes slow gastric emptying. Combined effects may produce delayed gastric emptying severe enough to cause aspiration risk during anesthesia, bezoar formation, or persistent vomiting

Pancreatitis. Acute pancreatitis is a labeled risk for GLP-1 class drugs. The amylin class adds theoretical pancreatic stress through its insulin co-secretion biology

Gallbladder events. Rapid weight loss increases gallstone risk. Both drug classes are independently associated with biliary events. Combined effect on gallbladder pathology is unknown

Hypoglycemia. Neither drug causes hypoglycemia at therapeutic doses in non-diabetic patients. In patients on insulin or sulfonylureas, the combination may produce harder-to-predict glucose lowering

Cardiovascular effects. Heart rate increases modestly with incretin drugs. The amylin component's cardiovascular profile is less characterized. Combined effects in patients with pre-existing arrhythmias or cardiomyopathy are not predictable

Mental health. Both classes have rare reports of mood disturbance and suicidal ideation in post-marketing or trial data. Combined risk is unknown